Clinical Edge Journal Scan

Osteoporosis remains highly prevalent in patients with RA


 

Key clinical point: The prevalence for osteoporosis continues to remain high in patients with rheumatoid arthritis (RA) despite significant advances in diagnostic methods, prevention, and treatment.

Major finding: Overall, osteoporosis was highly prevalent in patients with RA (prevalence, 27.6%; 95% CI, 23.9%-31.3%), with the prevalence being the highest in studies during 2011-2015 (36.2%; 95% CI, 24.5%-47.8%), followed by 2016-2021 (27.1%; 95% CI, 20.7%-33.4%), and before 2010 (21.6%; 95% CI, 15.8%-27.4%).

Study details: Findings are from a systematic review and meta-analysis of 57 studies including 227,812 patients with RA, of which 64,290 reported osteoporosis.

Disclosures: This study was funded by Arak University of Medical Sciences. The authors declared no conflicts of interest.

Source: Moshayedi S et al. The prevalence of osteoporosis in rheumatoid arthritis patient: A systematic review and meta-analysis. Sci Rep . 2022;12(1):15844 (Sep 23). Doi: 10.1038/s41598-022-20016-x.

Recommended Reading

JAK inhibitors show no excess cardiovascular safety signal in French nationwide cohort
MDedge Rheumatology
Ten-day methotrexate pause after COVID vaccine booster enhances immunity against Omicron variant
MDedge Rheumatology
Increased risk for severe COVID-19 in rheumatoid arthritis and its phenotypic subgroups
MDedge Rheumatology
RA in remission: Subclinical inflammation lower with cs/bDMARDs combination vs. monotherapy
MDedge Rheumatology
Withdrawing methotrexate increased disease activity without affecting remission rates in RA patients at target
MDedge Rheumatology
RA: Increased risk for VTE with JAK inhibitors
MDedge Rheumatology
Suboptimal early RA management predicts difficult-to-treat RA
MDedge Rheumatology
Smoking worsens disease outcomes in RA
MDedge Rheumatology
Patients with RA remain at higher risk for SARS-CoV-2 infection and severe outcomes
MDedge Rheumatology
RA: High serum IFNβ levels predict early relapse after bDMARD withdrawal
MDedge Rheumatology